Founded with a mission to revolutionize immuno-oncology and anti-inflammatory treatments, Macrophage Therapeutics (MT) focuses on developing precise therapeutics using its proprietary Activated Macrophage targeting platform. The company leverages a unique CD206 receptor-based delivery system to enhance the precision and efficacy of proven therapeutic agents, significantly reducing off-target toxicity. MT aims to provide innovative solutions in the healthcare market, particularly in the fields of cancer and chronic inflammatory diseases.
Macrophage Therapeutics has attracted notable investors and industry experts due to its groundbreaking approach. The company's achievements include the development of therapeutics with binding affinities 10,000 times greater than current best-in-class antibodies, which has positioned MT as a leader in targeted therapy innovation. The impact of MT's work is evident in its potential to transform treatment paradigms, offering more effective and safer options for patients suffering from severe medical conditions.
Quick Facts
When was Macrophage Therapeutics' last funding round?
Macrophage Therapeutics' most recent funding round was for $2.5M (USD) in March 2015.
How much disclosed funding has Macrophage Therapeutics raised?
As of Mar 13, 2015, Macrophage Therapeutics has disclosed funding of $2.5M (USD).
